Oral steroids for long-term use in cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Cheng, Katharine ^a   Ashby, Deborah ^b   Smyth, Rosalind L ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PLACEBO; PREDNISOLONE; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID;

BODY HEIGHT; BODY WEIGHT; CATARACT; CHRONIC DRUG ADMINISTRATION; CUSHINGOID SYNDROME; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLUCOSE INTOLERANCE; GROWTH RETARDATION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; LUNG COMPLICATION; LUNG FUNCTION; MULTIPLE FRACTURE; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; CHILD; DRUG EFFECT; EARLY TERMINATION OF CLINICAL TRIAL; FEMALE; GROWTH; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; SEX DIFFERENCE; COMPLICATION; DRUG EFFECTS; RESPIRATORY TRACT DISEASES;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; CHILD; CYSTIC FIBROSIS; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; GLUCOCORTICOIDS; GROWTH; HUMANS; MALE; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT DISEASES; SEX FACTORS;

EID: 84891689243     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000407.pub3     Document Type: Review

References (41)

1. Auerbach HS, Williams M, Kirkpatrick JA, Colten HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985;2(8457):686-8.
2. Donati MA, Haver K, Gerson W, Klein M, McLaughlin FJ, Wohl MEB. Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology 1990;9 (Suppl 5):322.
3. Eigen H, Rosenstein BJ, Fitzsimmons S, Schidlow DV, and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics 1995;126(4):515-23.
4. Hsu J, Kuhns LR. Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology 1991;Suppl 6:324.
5. Lai HC, FitzSimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine 2000;342(12):851-9.
6. Lai HC, Kosorok MR, Allen DB, FitzSimmons SC, Rosenstein BJ, Campbell PW, et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology 1999;28 (Suppl 19):297.
7. Rosenstein BJ, Eigen H. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 1991;87(2):245-6.
8. Greally P, Hussain PJ, Vergani D, Price JF. Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood 1994;71(1):35-9.
9. Greally P, Sampson AJ, Piper PJ, Price JF. Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal 1992;5(Suppl 15):259s.
10. Greally P, Sampson AP, Piper AJ, Price JF. Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12.
11. Cohen-Cymberknoh M, Blau H, Shoseyov D, Efrati O, Armoni S, Kerem E. Intravenous methylprednisolone pulse therapy vs. oral prednisone for allergic bronchopulmonary aspergillosis (ABPA) in CF [abstract]. Journal of Cystic Fibrosis 2008;7(Suppl 2):S58. [CFGD Register: PI219a; CRS-ID: 5500100000003257]
12. Cohen-Cymberknoh M, Blau H, Shoseyov D, Mei-Zahav M, Efrati O, Armoni S, et al. Intravenous monthly high-dose pulse methylprednisolone vs oral prednisone for therapy of allergic bronchopulmonary aspergillosis in cystic fibrosis [abstract]. American Journal of Respiratory and Critical Care Medicine 2009;179 Suppl:Abstract no: A1184. [CFGD Register: PI219b; CRS-ID: 5500100000010588]
13. Dovey M, Aitken ML, Emerson J, McNamara S, Dorman D, Gibson RL. A randomised, double-blind, placebo-controlled trial of oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbations [abstract]. Pediatric Pulmonology 2004;38 (Suppl 27):301.
14. Dovey M, Aitken ML, Emerson J, McNamara S, Waltz DA, Gibson RL. Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest 2007;132(4):1212-8.
15. Linnane SJ, Thin AG, Keatings VM, Moynihan JB, McLoughlin P, FitzGerald MX. Glucocorticoid treatment reduces exhaled nitric oxide in cystic fibrosis patients. European Respiratory Journal 2001;17(6):1267-70.
16. Pantin CFA, Stead RJ, Hodson ME, Batten JC. Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis. Thorax 1986;41(1):34-8.
17. Stead RJ, Pantin CFA, Hodson ME, Batten JC. Prednisolone in the treatment of airflow obstruction [abstract]. Proceedings of the 13th Annual Meeting of the European Working Group for Cystic Fibrosis; 1985 November 3-8; Jerusalem, Israel. 1985:112.
18. Kapustina T, Fedorova V, Voronkova A, Kapranov N. Long-term treatment with corticosteroids and bone mineral density in patients with cystic fibrosis [abstract]. European Respiratory Society Annual Congress; 2008 Oct 4-8; Berlin, Germany. 2008:214s.
19. Nyamugunduru G, Desai M, Rayner RJ, Simmonds E, Weller P, Spencer DA. A double blind parallel placebo-controlled randomised study of oral prednisolone in acute respiratory exacerbations in children with cystic fibrosis. Thorax 1998;53(Suppl 4):A61.
20. Nyamugunduru G, Desai M, Spencer D, Clarke J, Weller P. A double blind parallel placebo-controlled randomised study of the addition of short-course oral prednisolone in treatment of acute respiratory exacerbations in children with cystic fibrosis [abstract]. Proceedings of 22nd European Cystic Fibrosis Conference, 1998 June 13-18; Berlin. 1998:79.
21. Nyamugunduru G, Desai M, Weller P, Spencer DA. The effect of oral prednisolone on serum interleukin-8 concentrations in acute respiratory exacerbations in children with cystic fibrosis [abstract]. Proceedings of 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm. Stockholm, 2000:183.
22. Pukhalsky A, Shmarina G, Pukhalskaya D, Perederko L, Kashirskaya N, Kapranov N. Can different approaches to anti-inflammatory therapy result in different outcomes in cystic fibrosis patients? [abstract]. Proceedings of European Respiratory Society Annual Congress; 2007 Sep 15-19; Stockholm, Sweden. 2007:31s, Abstract no: E345. [CFGD Register: IB96; CRS-ID: 5500100000010731]
23. Pukhalsky A, Shmarina G, Pukhalskaya D, Perederko L. Whether low frequency of hepatobiliary abnormalities in cystic fibrosis patients is associated with anti-inflammatory treatment? [abstract]. European Respiratory Society Annual Congress; 2008 Oct 4-8; Berlin, Germany. 2008:216s.
24. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respiratory tract infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995;310(6994):1570-2.
25. Balfour-Lynn IM, Dinwiddie R. Role of corticosteroids in cystic fibrosis lung disease. Journal of the Royal Society of Medicine 1996;89(Suppl 27):8-13.
26. Donati MA, Haver K, Gerson W, Klein M, McLaughlin FJ, Wohl MEB. Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology 1990;Suppl 5:322.
27. Frisancho AR. Anthropometric standards for the assessment of growth and nutritional status. Ann Arbor: University of Michigan Press, 1990.
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
29. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
30. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DWH. Early pulmonary inflammation in infants with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1995;151(4):1075-82.
31. Konstan MW, Berger M. Infection and inflammation of the lung in cystic fibrosis. In: Davis PB editor(s). Cystic Fibrosis. New York: Marcel Dekker Inc, 1993.
32. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild disease suggesting ongoing infection and inflammation. American Journal of Respiratory and Critical Care Medicine 1994;150(2):448-54.
33. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology [abstract]. Proceedings of the 12th International Cystic Fibrosis Conference; 1996 June 16-21; Jerusalem. Jerusalem, 1996.
34. Lai HC, Kosorok MR, Allen DB, FitzSimmons SC, Rosenstein BJ, Campbell PW, et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology 1999;Suppl 19:297.
35. Lai HC, FitzSimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine 2000;342(12):851-9.
36. Llewellyn-Jones CG, Hill SL, Stockley RA. Effect of fluticasone proprionate on neutrophil chemotaxis, superoxide generation, and extracellular proteolytic activity in vitro. Thorax 1994;49(3):207-12.
37. Murray GD. Statistical aspects of research methodology. British Journal of Surgery 1991;78(7):777-81.
38. Schleimer RP. Effects of glucocorticoids on inflammatory cells relevant to their therapeutic applications in asthma. American Review of Respiratory Disease 1990;141:S59-S69.
39. Cheng K, Ashby D, Smyth RL. Oral steroids for cystic fibrosis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD000407]
40. Cheng K, Ashby D, Smyth RL. Oral steroids for long-term use in cystic fibrosis. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD000407.pub2]
41. Cheng K, Ashby D, Smyth RL. Oral steroids for long-term use in cystic fibrosis. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD000407.pub3]